Description: Botanix Pharmaceuticals Limited, formerly Bone Medical Limited, is a pharmaceutical company. The Company focuses on developing medical dermatology products for dermatologists and their patients. Its segments include Research & Development and Corporate. The Company's products and pipeline products are all based on drug delivery technology known as Permetrex, which helps solve the challenge of delivering active pharmaceutical ingredients across the skin. The Company's products, which are under development, are focused on modulating the body's endocannabinoid system of receptors which regulates skin function, growth and renewal. Its product pipeline includes BTX1503, BTX1308 and BTX1204. Its BTX1503 is a transdermal gel formulation used for the treatment of serious acne in adults and teenagers. Its BTX1308 is a transdermal gel formulation used for the treatment of plaque psoriasis. Its BTX1204 is a transdermal gel formation used for the treatment of atopic dermititis.
Home Page: www.botanixpharma.com
BOT Technical Analysis
D2, 661 Newcastle Street
Leederville,
WA
6007
Australia
Phone:
61 8 6555 2945
Officers
| Name | Title |
|---|---|
| Mr. Vincent P. Ippolito | MD & Exec. Chairman |
| Dr. Howie McKibbon | Chief Operating Officer |
| Dr. Henry William Bosch BA, Ph.D. | Chief Scientific Officer & Exec. Director |
| Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB | Exec. Director |
| Dr. Clarence L. Young M.D. | Chief Medical Officer |
| Ms. Lynda Berne | Head of Commercial |
| Dr. Jack Hoblitzell Ph.D. | Sr. VP of Pharmaceutical Devel. |
| Dr. Patricia S. Walker M.D., Ph.D. | Chief Medical Adviser |
| Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA | Company Sec. |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.6845 |
| Price-to-Sales TTM: | 24.57 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 11 |